RCT of Carvedilol Versus Variceal Band Ligation in the Primary Prophylaxis of Oesophageal Variceal Haemorrhage
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01070641|
Recruitment Status : Unknown
Verified February 2010 by Aga Khan University.
Recruitment status was: Recruiting
First Posted : February 18, 2010
Last Update Posted : February 18, 2010
Aim To compare Carvedilol with variceal band ligation in the prevention of first variceal bleed.
End points of trial Primary: Variceal hemorrhage Secondary: Death
Randomised controlled clinical trial. Results analysed for the above end points on an intention-to-treat basis.
|Condition or disease||Intervention/treatment||Phase|
|Portal Hypertension||Drug: Carvedilol Procedure: Esophageal variceal band ligation||Phase 4|
Patients from the Gastroenterology section of the Aga Khan University, Karachi, with liver cirrhosis and on endoscopy having grade II, or larger oesophageal varices and who have not bled previously from varices.
Method All suitable patients will be recruited after informed consent is given. Randomisation of treatment is by sealed envelopes prepared in batches of 20.
Carvedilol This will be administered as a once daily dose of 12.5mg.
Variceal band ligation Endoscopy will be performed ever two weeks until eradication of oesophageal varices. Eradication is achieved when no varices or only grade I varices (varices which are small and flatten on air insufflations in the oesophagus) are present. Subsequent endoscopy sessions will be progressively less frequent, at intervals of 3 months, 6 months and 12 months thereafter. Should varices recur, the protocol for eradication as described above will be re-instituted.
Follow-up This will take place in a dedicated clinic. First visit is six weeks after initiation of treatment and three monthly thereafter. Clinical and laboratory parameters will be obtained at each visit. All patients with alcoholic liver disease will be asked to provide an up-to-date status on drinking. Treatment will cease upon reaching any of these end-points: variceal haemorrhage, death or liver transplantation. Duration of follow-up is defined as time from randomisation to the above end points or to the last follow-up date available.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||148 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||RCT of Carvedilol vs Variceal Band Ligation in the Primary Prophylaxis of Oesophageal Variceal Haemorrhage|
|Study Start Date :||June 2002|
|Estimated Primary Completion Date :||February 2011|
|Estimated Study Completion Date :||July 2011|
Active Comparator: Carvedilol
Each patient will receive Carvedilol 12.5mg QD
Carvedilol 12.5mg QD
Other Name: carvida
Active Comparator: Esophageal Variceal Band Ligation
Each patient will undergo for serial esophageal variceal band ligations after 3 weeks of last session till the eradication of varices
Procedure: Esophageal variceal band ligation
Each patient will undergo for variceal band ligation after 3 weeks till the eradication of varices
Other Name: EVBL
- Variceal hemorrhage [ Time Frame: one year ]
- death [ Time Frame: one year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01070641
|Contact: Syed Hasnain A Shah, MBBS, FRCP||00922134930051 ext firstname.lastname@example.org|
|Aga Khan University Hospital||Recruiting|
|Karachi, Sindh, Pakistan, 74800|
|Contact: Syed Hasnain A Shah, MBBS, FRCP 00922134930051 ext 4676 email@example.com|
|Principal Investigator: Syed Hasnain A Shah, FRCP|
|Sub-Investigator: Amna Butt, MBBS, FCPS|
|Sub-Investigator: Ambreen Pyarali, MBBS|
|Principal Investigator:||Syed hasnain A Shah, MBBS, FRCP||Aga Khan University Hospital, Karachi|